Related Experiment Video
Updated: Jul 23, 2025
05:55
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
Published on: December 1, 2023
888
A place for biosimilars in the changing multiple sclerosis treatment landscape
Benjamin Greenberg1, Gavin Giovannoni2
1Department of Neurology and Department of Pediatrics, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390, USA.
Multiple Sclerosis and Related Disorders
|July 19, 2023
Summary
Biosimilar medicines offer a cost-effective alternative for multiple sclerosis (MS) treatment, providing the same efficacy and safety as reference biologics. Increased understanding and education are crucial for successful integration and improved patient access to these vital therapies.
Area of Science:
- Neuroimmunology
- Pharmacoeconomics
- Drug Development
Background:
- Multiple sclerosis (MS) treatment relies heavily on biologic disease-modifying therapies (DMTs).
- High treatment costs present a significant barrier to patient access.
- Upcoming patent expirations for key MS biologics will allow biosimilar entry.
Purpose of the Study:
- To review biosimilar medicines and their potential integration into the MS treatment landscape.
- To leverage existing experience with biosimilars from other therapy areas.
- To inform healthcare providers and patients about biosimilar adoption in MS.
Main Methods:
- Literature review of biosimilar medicines.
- Analysis of existing biosimilar data across multiple therapeutic areas.
- Discussion of regulatory pathways and clinical integration strategies.
Main Results:
- Lack of awareness exists regarding differences between drug types and biosimilars.
- Biosimilars demonstrate matching efficacy and safety profiles to reference biologics.
- Successful integration requires understanding stringent approval processes and education.
- Biosimilars can lead to significant cost savings and expand patient access to DMTs.
Conclusions:
- Clinicians and patients need to understand biosimilar fundamentals for optimized MS treatment.
- Biosimilars offer consistent treatment outcomes, matching reference biologics.
- Biosimilar medicines can reduce access barriers by providing cost-effective alternatives.
More Related Videos
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
174
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
174
01:29Microorganisms in Medicine and Therapeutics
60
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
60
01:16Bioequivalence: Overview
1.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:22iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
148
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
148